SCHEMBL3754190

SCHEMBL3754190

O=C1CCc2cc(O)ccc2O1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.51
PBRM1 Q86U86 1/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
ALDH1A1 P00352 6/20 0.43
HPGD P15428 5/20 0.43
HSD17B10 Q99714 2/20 0.43
GAA P10253 1/20 0.43
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
PRKCI P41743 1/20 0.42
GLA P06280 2/20 0.41
ALDH2 P05091 1/20 0.41
ALDH3A1 P30838 1/20 0.41
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MIF P14174 2/20 0.40
CYP3A4 P08684 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749724 1.00 PTGS2 (0.51) PTGS2PBRM1ESR1ESR2ALDH1A1
SCHEMBL1013856 0.85 CA2 (0.50) PBRM1ESR1ESR2ALDH1A1HPGD
SCHEMBL29448284 0.85 CA2 (0.50) PBRM1ESR1ESR2ALDH1A1HPGD
Homogenestic Acid Lactone SCHEMBL31756861 0.82 MAOA (0.49) PTGS2ALDH1A1HPGDHSD17B10GAA
Homogenestic Acid Lactone SCHEMBL2460842 0.82 MAOA (0.49) PTGS2ALDH1A1HPGDHSD17B10GAA
SCHEMBL1984098 0.81 AHR (0.43) HPGDHSD17B10MAOAMAOBGLA
SCHEMBL2957000 0.80 MEN1 (0.47) PTGS2ALDH1A1HPGDGAAMAOA
SCHEMBL2965162 0.79 PTGS2 (0.42) PTGS2ALDH1A1HPGDMAOAMAOB
SCHEMBL9289705 0.78 PTGS2 (0.46) PTGS2PBRM1ESR1ESR2ALDH1A1
SCHEMBL19227826 0.78 ALDH2 (0.39) PTGS2HPGDHSD17B10MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4587583-A1 COVALENTLY MODIFIED TEMPLATE-INDEPENDENT DNA POLYMERASE AND METHODS OF USE THEREOF The Charles Stark Draper Laboratory, Inc. (US) 2025-07-23 EP disclosed
WO-2024059703-A1 COVALENTLY MODIFIED TEMPLATE-INDEPENDENT DNA POLYMERASE AND METHODS OF USE THEREOF THE CHARLES STARK DRAPER LABORATORY, INC. (US) 2024-03-21 WO disclosed
CN-117511579-A Biomass pyrolysis method and device 华陆工程科技有限责任公司 2024-02-06 CN disclosed
US-20210030022-A1 NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS DSM IP ASSETS B.V. (NL) 2021-02-04 US disclosed
US-9620363-B2 Underlayer film-forming composition and pattern forming process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-04-11 US disclosed
US-9620363-B2 Underlayer film-forming composition and pattern forming process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-04-11 US disclosed
US-20160339263-A1 SKIN LIGHTENER IN PHOTOTHERAPY MERCK PATENT GMBH (DE) 2016-11-24 US disclosed
EP-2813891-A2 Photoresist underlayer film-forming composition and pattern forming process Shin-Etsu Chemical Co., Ltd. (JP) 2014-12-17 EP disclosed
US-20140363956-A1 UNDERLAYER FILM-FORMING COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2014-12-11 US disclosed
US-20140363956-A1 UNDERLAYER FILM-FORMING COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2014-12-11 US disclosed
EP-0912534-A1 MUSCARINIC ANTAGONISTS SCHERING CORPORATION (US) 1999-05-06 EP disclosed
WO-1998000412-A9 MUSCARINIC ANTAGONISTS 1998-07-09 WO disclosed
WO-1998000412-A1 MUSCARINIC ANTAGONISTS SCHERING CORPORATION (US) 1998-01-08 WO disclosed
CN-1106013-A Therapeutic or preventive agents for diseases associated with peroxyli peroxylipid MITSUI TOATSU CHEMICALS (JP) 1995-08-02 CN disclosed
US-5434186-A Antiinflammatory agents HOFFMANN-LA ROCHE INC. (US) 1995-07-18 US disclosed
US-5273999-A A 4-keto-boroalkyleneoxychroman or 2,3-dihydrobenzofuran derivative HOFFMANN-LA ROCHE INC. (US) 1993-12-28 US disclosed
EP-0531823-A1 Bicyclic carboxylic acid derivatives as anti-inflammatory agents F. HOFFMANN-LA ROCHE AG (CH) 1993-03-17 EP disclosed
US-4780478-A Aminopropoxy-chromones useful as antidepressants MERCK PATENT GESELLSCHAFT MIT BERSCHRANKTER HAFTUNG (DE) 1988-10-25 US disclosed
US-4508732-A Basic ethers useful as antidepressant agents MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1985-04-02 US disclosed
US-4376123-A Hexahydroazepinyloxy-chromones useful as antidepressants MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1983-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210030022-A1 NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS KMO, FFAR3, ACOX3 PTGS2 2044/4885PBRM1 3330/4885ESR1 2896/4885
US-20160339263-A1 SKIN LIGHTENER IN PHOTOTHERAPY TYR, MC1R, CUTA PTGS2 590/4885PBRM1 3050/4885ESR1 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.